Bernard E. Weissman

University of North Carolina at Chapel Hill School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a rare, deadly form of ovarian cancer that uniformly harbors mutations in SMARCA4, a member of the SWI/SNF chromatin remodeling complex. SWI/SNF impacts RNA splicing, and dysregulation of splicing can generate immunogenic tumor antigens. In this study, we explored the relationship between SMARCA4 loss and RNA splicing dysregulation. SCCOHT primary tumors harbored tumor-associated outlier splicing events compared with normal tissues. Many of the tumor events were retained introns encoding novel peptides predicted to bind to MHC-I complexes. Immune cells were observed in primary SCCOHT tumors, suggesting a potentially immune-reactive tumor microenvironment. Mutations in several switch/sucrose nonfermenting (SWI/SNF) subunits were associated with higher rates of outlier retained introns across tumor types in The Cancer Genome Atlas data. Interestingly, RNA sequencing of isogenic SCCOHT cell lines demonstrated a role for SMARCA4 in intron retention (IR). Distinct protein–protein interactions between splicing factors identified in SCCOHT cell lines supported a role for SMARCA4 in splicing regulation. Furthermore, SWI/SNF localized to genes, which were differentially spliced. Mass spectrometry analyses confirmed expression of some of these novel peptides, and a subset of these are predicted to bind to MHC-I complexes. A pool of these novel peptides derived from retained introns in SCCOHT triggered proliferation and expression of TNFα and INFγ in primary human T cells. Together, these data suggest that SMARCA4 loss in SCCOHT leads to IR. Furthermore, T-cell activation by novel peptides encoded by these tumor-specific splicing events suggests IR could be a source of tumor-associated antigens in SCCOHT. Significance: SCCOHT, a rare ovarian cancer, features splicing dysregulation due to SMARCA4 loss that generates immunostimulatory peptides linked to potential immune responses and therapeutic avenues, challenging traditional views of the role of SMARCA4.

Year:

2025

The DNA repair protein RAD18 activates ‘Y-family’ Trans-Lesion Synthesis (TLS) DNA polymerases that are DNA damage-tolerant and potentially error-prone. RAD18 is also frequently overexpressed and pathologically activated in cancer cells. However, the extent to which RAD18 shapes cancer genomes and impacts tumorigenesis is unclear. Therefore, we tested the effect of Rad18 status on chemically-induced and oncogene-driven tumorigenesis. In a chemically-induced oral carcinogenesis model, acute (2-16 days) 4NQO-treatment induces expression of Rad18 and TLS polymerase mRNAs in mouse oral epithelial cells prior to emergence of oral squamous cell carcinomas (OSCCs). Chronic (8 week) 4NQO-treatment leads to onset of oral tumors that is accelerated in Rad18 -/- mice when compared with Rad18 +/+ animals. Analysis of OSCC exomes reveals increased levels of G(C)>T(A) transversions in Rad18 -/- tumors when compared with Rad18 +/+ . Therefore, Rad18 promotes error-free bypass of 4NQO-induced DNA lesions and suppresses 4NQO-induced oral carcinogenesis. In a Kras G12D -induced lung carcinogenesis model, Rad18 -deficiency did not affect rates or incidence of oncogene-induced lung tumors or mutations. Taken together, we demonstrate that Rad18 has context-specific tumor-suppressive activity. Given the prevalence of 4NQO-like environmental exposures, RAD18 is highly likely to shape human cancer genomes and perhaps influence other aspects of the tumorigenic process.

Year:

2025

Aberrant activation of the NRF2/NFE2L2 transcription factor commonly occurs in head and neck squamous cell carcinomas (HNSCC). Mouse model studies have shown that NRF2 activation alone does not result in cancer. When combined with classic oncogenes and at the right dose, NRF2 activation promotes tumor initiation and progression. Here we deleted the tumor suppressor genes p16INK4A and p53 (referred to as CP mice), which are commonly lost in human HNSCC, in the presence of a constitutively active NRF2E79Q mutant (CPN mice). NRF2E79Q expression in CPN mice resulted in squamous cell hyperplasia or dysplasia with hyperkeratosis in the esophagus, oropharynx, and forestomach. In addition, CPN mice displayed oral cavity squamous cell carcinoma (OSCC); CP mice bearing wild-type NRF2 expression did not develop oral cavity hyperplasia, dysplasia or OSCC. In both CP and CPN mice, we also observed predominantly abdominal sarcomas and carcinomas. Our data show that in the context of p53 and p16 tumor suppressor loss, NRF2 activation serves oncogenic functions to drive OSCC. CPN mice represent a new model for OSCC that closely reflects the genetics of human HNSCC. Significance: Human squamous cancers frequently show constitutive NRF2 activation, associated with poorer outcomes and resistance to multiple therapies. Here, we report the first activated NRF2-driven and human-relevant mouse model of squamous cell carcinoma that develops in the background of p16 and p53 loss. The availability of this model will lead to a clearer understanding of how NRF2 contributes to the initiation, progression, and therapeutic response of OSCC.

Year:

2024

Purpose: Large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine malignancy that, like small cell lung cancer (SCLC), is associated with the absence of druggable oncogenic drivers and dismal prognosis. In contrast to SCLC, however, there is little evidence to guide optimal treatment strategies, which are often adapted from SCLC and non–small cell lung cancer approaches. Experimental Design: To better define the biology of LCNEC, we analyzed cell line and patient genomic data and performed IHC and single-cell RNA sequencing of core needle biopsies from patients with LCNEC and preclinical models. Results: In this study, we demonstrate that the presence or absence of YAP1 distinguishes two subsets of LCNEC. The YAP1-high subset is mesenchymal and inflamed and is characterized, alongside TP53 mutations, by co-occurring alterations in CDKN2A/B and SMARCA4 . Therapeutically, the YAP1-high subset demonstrates vulnerability to MEK- and AXL-targeting strategies, including a novel preclinical AXL chimeric antigen receptor–expressing T cell. Meanwhile, the YAP1-low subset is epithelial and immune-cold and more commonly features TP53 and RB1 co-mutations, similar to those observed in pure SCLC. Notably, the YAP1 -low subset is also characterized by the expression of SCLC subtype–defining transcription factors, especially ASCL1 and NEUROD1 , and as expected, given its transcriptional similarities to SCLC, exhibits putative vulnerabilities reminiscent of SCLC, including delta-like ligand 3 and CD56 targeting, as is with novel preclinical delta-like ligand 3 and CD56 chimeric antigen receptor–expressing T cells, and DNA damage repair inhibition. Conclusions: YAP1 defines distinct subsets of LCNEC with unique biology. These findings highlight the potential for YAP1 to guide personalized treatment strategies for LCNEC.

Year:

2024

Aberrant activation of the NRF2/NFE2L2 transcription factor commonly occurs in head and neck squamous cell carcinomas (HNSCC). Mouse model studies have shown that NRF2 activation alone does not result in cancer. When combined with classic oncogenes and at the right dose, NRF2 activation promotes tumor initiation and progression. Here we deleted the tumor suppressor genes p16 INK4A and p53 (referred to as CP mice), which are commonly lost in human HNSCC, in the presence of a constitutively active NRF2 E79Q mutant (CPN mice). NRF2 E79Q expression in CPN mice resulted in squamous cell hyperplasia or dysplasia with hyperkeratosis in the esophagus, oropharynx, and forestomach. In addition, CPN mice displayed oral cavity squamous cell carcinoma (OSCC); CP mice bearing wild-type NRF2 expression did not develop oral cavity hyperplasia, dysplasia or OSCC. In both CP and CPN mice, we also observed predominantly abdominal sarcomas and carcinomas. Our data show that in the context of p53 and p16 tumor suppressor loss, NRF2 activation serves oncogenic functions to drive OSCC. CPN mice represent a new model for OSCC that closely reflects the genetics of human HNSCC. Significance: Human squamous cancers frequently show constitutive NRF2 activation, associated with poorer outcomes and resistance to multiple therapies. Here, we report the first activated NRF2-driven and human-relevant mouse model of squamous cell carcinoma that develops in the background of p16 and p53 loss. The availability of this model will lead to a clearer understanding of how NRF2 contributes to the initiation, progression, and therapeutic response of OSCC.

Year:

2024

NRF2 activity in human OSCC. TP53, CDKN2A, and NRF2 pathway mutational profiles from 268 HPV—oral cavity squamous cell carcinoma in TCGA. A, Waterfall plot—relative frequency and mutational classes. Color—mutational class. B, Kaplan–Meier plot—disease specific survival of the 254 patients with HPV—oral cavity squamous cell carcinoma with available outcomes data, stratified by NRF2 pathway alteration status. Red—Altered NRF2 pathway. Blue—wild-type NRF2 pathway. P value represents log-rank test. HR—hazard ratio with 95% confidence interval.

Year:

2024

Characterization of oral squamous cell carcinomas from CPN mice. Invasive OSCC from a CPN mouse stained for H&E ( A ). B, NRF2. PANCK ( C ) and vimentin ( D ). Scale bar = 200 µm. Images were taken using a BX61-Neville microscope.

Year:

2024

Histologic profile of normal and epithelial lesions of the oral mucosa from CP and CPN mice. Normal epithelium (CP; A ); epithelial hyperplasia with hyperkeratosis (CPN; B ); CPN ( C ); and oral squamous cell carcinoma (CPN; D ). Scale bar = 50 µm. Images were taken using an Olympus DP38 digital camera on an Olympus BX46 microscope.

Year:

2024

NRF2 activity in human OSCC. TP53, CDKN2A, and NRF2 pathway mutational profiles from 268 HPV—oral cavity squamous cell carcinoma in TCGA. A, Waterfall plot—relative frequency and mutational classes. Color—mutational class. B, Kaplan–Meier plot—disease specific survival of the 254 patients with HPV—oral cavity squamous cell carcinoma with available outcomes data, stratified by NRF2 pathway alteration status. Red—Altered NRF2 pathway. Blue—wild-type NRF2 pathway. P value represents log-rank test. HR—hazard ratio with 95% confidence interval.

Year:

2024

Targeted proteomic analyses of oral cavity tissues from CP and CPN mice. A, Heat map of protein expression from oral tissues of CP ( K14-Cre ERTAM2 ; p16 − / − ; p53 − / − ) and CPN ( K14-Cre ERTAM2 ; p16 − / − ; p53 − / − ; NRF2 E79Q/WT ) mice, with columns normalized by Z-scores; protein abundances were measured by IS-PRM. See also Supplementary Table S5 . B, PCA plot from protein abundances shown in A; the first two principal components explained 35% and 27% of the total variance respectively. C, Plot of the NRF2 score in CP and CPN mice. The score was calculated using 10 NRF2 targets within the first principal component. D, Correlation of the NQO1 protein expression with the NRF2 pathway score. E, Correlation of the SRXN1 protein expression with the NRF2 pathway score. F, Correlation of the IL36G protein expression with the NRF2 pathway score. For correlations of all proteins correlated with the NRF2 score, see Supplementary Fig. S4 . G, Box-and-whisker plots of protein abundance in CP and CPN oral cavity tissues. For box-and-whisker plots of abundance for all proteins, see Supplementary Fig. S5 . Adjusted P values were calculated with a Mann–Whitney U test. The normal tissue from the oral cavity of the CPN mice showed hyperplasia with hyperkeratosis as shown in Fig. 2B .

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (20)

Di Wu

Associate Professor

University of North Carolina

UNITED STATES
View details

Yuri Fedoriw

University of North Carolina, Lineberger Comprehensive Cancer Center

UNITED STATES
View details

Lauren A. Byers

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ritin Sharma

Staff Scientist

Translational Genomics Research Institute

UNITED STATES
View details

Samera Hamad

Assistant Professor

Cooper Medical School of Rowan University

UNITED STATES
View details

Michael Major

Alan A. and Edith L. Wolff Professor

Washington University in St. Louis

UNITED STATES
View details

Scott Williams

Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Rani Sellers

University of North Carolina at Chapel Hill School of Medicine

UNITED STATES
View details

John V. Heymach

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lynda Bennett

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Michael Frumovitz

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jing Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marcin Kortylewski

Professor

Beckman Research Institute, City of Hope

UNITED STATES
View details

Natalie Vokes

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

LI SHEN

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jessica Lang

Assistant Professor

University of Wisconsin-Madison

UNITED STATES
View details

Yemin Wang

Assistant Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Don L. Gibbons

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David G. Huntsman

The University of British Columbia

CANADA
View details

Paul Zolkind

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details